TYK MEDICINES-B Secures Conditional NMPA Approval for Its Novel EGFR-TKI Therapy

Stock News08-27 21:26

TYK MEDICINES-B (02410) has announced that its independently developed next-generation EGFR-TKI innovative drug, Duxenaitinib Mesylate Tablets (TY-9591), has received conditional marketing approval from China's National Medical Products Administration (NMPA).

The approved indication covers first-line treatment for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 19 deletions (19DEL) or exon 21 (L858R) substitution mutations, accompanied by central nervous system (CNS) metastases.

Duxenaitinib Mesylate Tablets represent a novel, highly selective, irreversible oral EGFR-TKI independently developed by the company, positioned as a differentiated deuterated innovation of osimertinib. Through unique structural optimization, the drug effectively reduces the generation of toxic metabolites while demonstrating superior pharmacokinetic properties, showcasing remarkable clinical efficacy and safety advantages in lung cancer patients with brain metastases carrying EGFR 19del and L858R sensitive mutations.

The company has already established a comprehensive clinical development program around this product, encompassing multiple monotherapy and combination therapy studies that extensively cover various niche indications within advanced non-small cell lung cancer.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1191561333?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-27 21:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1191561333","market":"hk","top_or_hot":-1,"title":"TYK MEDICINES-B Secures Conditional NMPA Approval for Its Novel EGFR-TKI Therapy","media":"Stock News","content":"<p><b>TYK MEDICINES-B</b> (02410) has announced that its independently developed next-generation EGFR-TKI innovative drug, Duxenaitinib Mesylate Tablets (TY-9591), has received conditional marketing approval from China's National Medical Products Administration (NMPA).<br><br>The approved indication covers first-line treatment for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 19 deletions (19DEL) or exon 21 (L858R) substitution mutations, accompanied by central nervous system (CNS) metastases.<br><br>Duxenaitinib Mesylate Tablets represent a novel, highly selective, irreversible oral EGFR-TKI independently developed by the company, positioned as a differentiated deuterated innovation of osimertinib. Through unique structural optimization, the drug effectively reduces the generation of toxic metabolites while demonstrating superior pharmacokinetic properties, showcasing remarkable clinical efficacy and safety advantages in lung cancer patients with brain metastases carrying EGFR 19del and L858R sensitive mutations.<br><br>The company has already established a comprehensive clinical development program around this product, encompassing multiple monotherapy and combination therapy studies that extensively cover various niche indications within advanced non-small cell lung cancer.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TYK MEDICINES-B Secures Conditional NMPA Approval for Its Novel EGFR-TKI Therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTYK MEDICINES-B Secures Conditional NMPA Approval for Its Novel EGFR-TKI Therapy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-08-27 21:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>TYK MEDICINES-B</b> (02410) has announced that its independently developed next-generation EGFR-TKI innovative drug, Duxenaitinib Mesylate Tablets (TY-9591), has received conditional marketing approval from China's National Medical Products Administration (NMPA).<br><br>The approved indication covers first-line treatment for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 19 deletions (19DEL) or exon 21 (L858R) substitution mutations, accompanied by central nervous system (CNS) metastases.<br><br>Duxenaitinib Mesylate Tablets represent a novel, highly selective, irreversible oral EGFR-TKI independently developed by the company, positioned as a differentiated deuterated innovation of osimertinib. Through unique structural optimization, the drug effectively reduces the generation of toxic metabolites while demonstrating superior pharmacokinetic properties, showcasing remarkable clinical efficacy and safety advantages in lung cancer patients with brain metastases carrying EGFR 19del and L858R sensitive mutations.<br><br>The company has already established a comprehensive clinical development program around this product, encompassing multiple monotherapy and combination therapy studies that extensively cover various niche indications within advanced non-small cell lung cancer.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IPOS","symbol_name":"Renaissance International IPO ETF","start_time":0,"source_url":"","article_id":"1191561333","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1191561333","pubTimestamp":1787837163,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"TYK MEDICINES-B (02410) has announced that its independently developed next-generation EGFR-TKI innovative drug, Duxenaitinib Mesylate Tablets (TY-9591), has received conditional marketing approval...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159938":"医药","IPOS":"Renaissance International IPO ETF","BK1515":"抗疫概念","BK1161":"生物科技","09939":"开拓药业-B","BK1574":"生物医药B类股","02410":"同源康医药-B"},"translate_title":"TYK MEDICINES-B 的新型 EGFR-TKI 疗法获得 NMPA 有条件批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1,"09939":1,"02410":1,"IPOS":1},"content_text":"TYK MEDICINES-B (02410) has announced that its independently developed next-generation EGFR-TKI innovative drug, Duxenaitinib Mesylate Tablets (TY-9591), has received conditional marketing approval from China's National Medical Products Administration (NMPA).The approved indication covers first-line treatment for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 19 deletions (19DEL) or exon 21 (L858R) substitution mutations, accompanied by central nervous system (CNS) metastases.Duxenaitinib Mesylate Tablets represent a novel, highly selective, irreversible oral EGFR-TKI independently developed by the company, positioned as a differentiated deuterated innovation of osimertinib. Through unique structural optimization, the drug effectively reduces the generation of toxic metabolites while demonstrating superior pharmacokinetic properties, showcasing remarkable clinical efficacy and safety advantages in lung cancer patients with brain metastases carrying EGFR 19del and L858R sensitive mutations.The company has already established a comprehensive clinical development program around this product, encompassing multiple monotherapy and combination therapy studies that extensively cover various niche indications within advanced non-small cell lung cancer.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.48.0","shortVersion":"4.48.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1191561333","isCrawlerRequest":true}